Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS)

CNY 21.47

(6.93%)

Market Cap (In CNY)

9.77 Billion

Revenue (In CNY)

1.58 Billion

Net Income (In CNY)

106.45 Million

Avg. Volume

8.81 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12.88-24.08
PE
-
EPS
-
Beta Value
0.387
ISIN
CNE000000545
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Hongqi Wang
Employee Count
-
Website
https://www.vcanbio.com
Ipo Date
1993-05-04
Details
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, safe medication guide gene testing for children and adults, disease genetic testing, disease susceptibility gene testing, etc.; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents; and in vitro diagnostic reagents and medical devices. Vcanbio Cell & Gene Engineering Corp., Ltd was founded in 1992 and is based in Tianjin, the People's Republic of China.